- Home
- JNVR vs GNPX Comparison
JNVR vs GNPX Comparison
Compare JNVR & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- GNPX
- Stock Information
- Founded
- JNVR 2018
- GNPX 2009
- Country
- JNVR United States
- GNPX United States
- Employees
- JNVR N/A
- GNPX N/A
- Industry
- JNVR Finance: Consumer Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- GNPX Health Care
- Exchange
- JNVR Nasdaq
- GNPX Nasdaq
- Market Cap
- JNVR 93.3M
- GNPX 7.0M
- IPO Year
- JNVR 2023
- GNPX 2018
- Fundamental
- Price
- JNVR $63.99
- GNPX $0.29
- Analyst Decision
- JNVR
- GNPX Strong Buy
- Analyst Count
- JNVR 0
- GNPX 1
- Target Price
- JNVR N/A
- GNPX $10.00
- AVG Volume (30 Days)
- JNVR 1.9M
- GNPX 2.6M
- Earning Date
- JNVR 05-13-2025
- GNPX 05-16-2025
- Dividend Yield
- JNVR N/A
- GNPX N/A
- EPS Growth
- JNVR N/A
- GNPX N/A
- EPS
- JNVR N/A
- GNPX N/A
- Revenue
- JNVR $2,099,660.00
- GNPX N/A
- Revenue This Year
- JNVR N/A
- GNPX N/A
- Revenue Next Year
- JNVR N/A
- GNPX N/A
- P/E Ratio
- JNVR N/A
- GNPX N/A
- Revenue Growth
- JNVR 4.82
- GNPX N/A
- 52 Week Low
- JNVR $3.37
- GNPX $0.22
- 52 Week High
- JNVR $91.38
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- JNVR 57.60
- GNPX 48.94
- Support Level
- JNVR $64.09
- GNPX $0.27
- Resistance Level
- JNVR $91.38
- GNPX $0.36
- Average True Range (ATR)
- JNVR 14.99
- GNPX 0.03
- MACD
- JNVR -0.59
- GNPX 0.01
- Stochastic Oscillator
- JNVR 53.59
- GNPX 47.45
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from platform fees and subscription revenue.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.